Matrix Laboratories signs Licensing Agreement with Gilead

Matrix Laboratories Ltd has announced that the Company signed a Licensing Agreement with Gilead on September 22, 2006, for manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate using Gilead’s proprietary technology. Tenofovir is a well established therapy for second-line treatment of HIV/AIDS and has recently been endorsed by WHO for first-line treatment as well. It is characterized by low incidence of resistance as compared to other first-line therapies.

The Company will have access to Gilead’s technology for manufacture and sale of Tenofovir in 95 countries including India. In addition, the Company will be able to make cost-saving modifications to the technology to enable improved access to the developing world. The Company will also have the right to develop combination therapies using Tenofovir to enhance the effectiveness of existing therapies.

This license further boosts the Company's significant portfolio of anti-retroviral APIs developed for combating HIV/AIDS.

Source : Equity Bulls

Keywords